| ? |
37v-16
|
|
|
unclassified
|
RBRC
|
10
|
Obfc2bGt(37v-16)
|
Gene trap 37v-16
|
oligonucleotide/oligosaccharide-binding fold containing 2B
|
gene trap
|
| ? |
BayGenomics ES cell line XH859
|
|
|
unclassified
|
MMRRC
|
10
|
Obfc2bGt(XH859)Byg
|
gene trap XH859, BayGenomics
|
oligonucleotide/oligosaccharide-binding fold containing 2B
|
gene trap
|
| ? |
C57BL/6N-Obfc2bGt(IST11327H10)Tigm
|
|
|
unclassified
|
TIGM
|
10
|
Gt(IST11327H10)Tigm
|
gene trap IST11327H10, Texas A&M Institute for Genomic Medicine
|
oligonucleotide/oligosaccharide-binding fold containing 2B
|
gene trap
|
| ? |
C57BL/6N-Obfc2bGt(IST12131A5)Tigm
|
|
|
unclassified
|
TIGM
|
10
|
Obfc2bGt(IST12131A5)Tigm
|
gene trap IST12131A5, Texas A&M Institute for Genomic Medicine
|
oligonucleotide/oligosaccharide-binding fold containing 2B
|
gene trap
|
| ? |
MFGC ES cell line GT-PST12290-NL
|
|
|
unclassified
|
CMMR
|
10
|
Gt (PST12290) Mfgc
|
gene trap PST12290, Mammalian Functional Genomics Centre
|
oligonucleotide/oligosaccharide-binding fold containing 2B
|
gene trap
|
| ? |
Obfc2btm1e(KOMP)Wtsi
|
|
|
mutant strain
|
KOMP
|
10
|
Obfc2btm1e(KOMP)Wtsi
|
targeted mutation 1e, Wellcome Trust Sanger Institute
|
oligonucleotide/oligosaccharide-binding fold containing 2B
|
targeted mutation
|
| 10
|
Obfc2btm1a(KOMP)Wtsi
|
targeted mutation 1a, Wellcome Trust Sanger Institute
|
oligonucleotide/oligosaccharide-binding fold containing 2B
|
targeted mutation
|
| ? |
SIGTR ES cell line DC0071
|
|
|
unclassified
|
MMRRC
|
10
|
Obfc2bGt(DC0071)Wtsi
|
gene trap DC0071, Wellcome Trust Sanger Institute
|
oligonucleotide/oligosaccharide-binding fold containing 2B
|
gene trap
|